E Wieland
Overview
Explore the profile of E Wieland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ott M, Berbalk K, Plecko T, Wieland E, Shipkova M
Clin Mass Spectrom
. 2024 Aug;
4-5:11-18.
PMID: 39193128
Urine screening can be used to detect misuse of illicit drugs and validate opioid replacement therapy compliance. It is common that immunochemical assays are combined with GC-MS for these applications....
2.
Mancini A, Wieland E, Geng G, Lothenbach B, Wehrli B, Dahn R
J Colloid Interface Sci
. 2021 Dec;
611:773.
PMID: 34895728
No abstract available.
3.
Mancini A, Wieland E, Geng G, Lothenbach B, Wehrli B, Dahn R
J Colloid Interface Sci
. 2020 Dec;
588:692-704.
PMID: 33309242
Fe(II) interaction with cement phases was studied by means of co-precipitation and sorption experiments in combination with X-ray absorption fine structure (XAFS) spectroscopy. Oxidation of Fe(II) was fast in alkaline...
4.
Guillemot T, Salazar G, Cvetkovic B, Kunz D, Szidat S, Wieland E
Analyst
. 2020 Oct;
145(24):7870-7883.
PMID: 33074269
Compound-specific radiocarbon analysis (CSRA) was developed to identify and quantify gaseous 14C-bearing carbon compounds at the pico- to femtomolar concentration range and employed in a corrosion experiment with small specimens...
5.
Cvetkovic B, Salazar G, Kunz D, Szidat S, Wieland E
Analyst
. 2018 Jun;
143(13):3059-3067.
PMID: 29850670
The combination of ion chromatography (IC) with accelerator mass spectrometry (AMS) was developed to determine the speciation of 14C-(radiocarbon) bearing organic compounds in the femto to pico molar concentration range....
6.
Rojo H, Scheinost A, Lothenbach B, Laube A, Wieland E, Tits J
Dalton Trans
. 2018 Feb;
47(12):4209-4218.
PMID: 29480307
Safety assessment studies of future nuclear waste repositories carried out in many countries predict selenium-79 to be a critical radionuclide due to its presence as anion in three relevant oxidation...
7.
Beck J, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U, et al.
Transplant Proc
. 2015 Nov;
47(8):2400-3.
PMID: 26518940
Background: In solid organ transplantation, sensitive real-time biomarkers to assess the graft health are desirable to enable early intervention, for example, to avoid full-blown rejections. During rejection, high amounts of...
8.
Huttemann M, Shipkova M, Klett C, Hasche G, Wilhelm J, Bolley R, et al.
Transplant Proc
. 2013 Jun;
45(4):1611-3.
PMID: 23726631
Plasma concentrations of A771726, the active moiety of leflunomide, have been suggested to be associated with antiviral efficacy and/or an increased risk of toxicity. A771726 is >99% bound to serum...
9.
Schettler V, Neumann C, Hagenah G, Schulz E, Wieland E
Atheroscler Suppl
. 2013 Jan;
14(1):89-92.
PMID: 23357148
Background: Lipoprotein apheresis (LA) is used in hypercholesterolemic patients suffering from cardiovascular disease (CHD) if a modified diet and lipid-lowering drug regimens had failed. During the first LA treatments LDL-cholesterol...
10.
Neumann C, Schulz E, Hagenah G, Platzer U, Wieland E, Schettler V
Atheroscler Suppl
. 2013 Jan;
14(1):29-32.
PMID: 23357137
Lipoprotein apheresis is a well-established extracorporeal treatment in modality of severe hyperlipoproteinemia. Besides the reduction of LDL cholesterol and modifications to physiology of lipoprotein and lipid metabolism, Lipoprotein apheresis may...